A novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing ...

In the Phase III VISIONARY study, sibeprenlimab, an investigational monoclonal antibody, showed a 51.2% reduction in ...

A Form 8-K outlining the full terms of the new credit facility will be filed with the Securities and Exchange Commission.

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN) in adults.

The US Food and Drug Administration (FDA) has accepted Otsuka Pharmaceutical’s biologics licence application for ...

Vyvgart for subcutaneous injection is available as a vial or prefilled ... active treatment within the past six months or newly diagnosed) or being treated with immunoglobulin therapy or ...

VYVGART for subcutaneous injection is available as a vial or prefilled ... active treatment within the past six months or newly diagnosed) or being treated with immunoglobulin therapy or ...

The 12–month study involved 233 subjects, including 217 patients under the age of 18. Only 14% of the patients who received subcutaneous injections of immunoglobulin missed work or study due to ...

The approval of subcutaneous immunoglobulin (SCIg) in 2006 further revolutionized ... Whereas SCIg requires more frequent infusions and multiple injection sites, its reduced systemic reactions and ...

HYQVIA ® is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10% and one vial of Recombinant Human Hyaluronidase ...

"We are very pleased that patients in Japan with agammaglobulinemia or hypogammaglobulinemia can now access HYQVIA, which represents the first and only subcutaneous immunoglobulin therapy that ...